Quince Therapeutics Inc
QNCX
Company Profile
Business description
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
Contact
611 Gateway Boulevard
Suite 273
South San FranciscoCA94080
USAT: +1 415 910-5717
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
32
Stocks News & Analysis
video
Do you qualify as 'rich'?
Morningstar's Sim Mody speaks with Mark LaMonica about the varying definitions of rich.
stocks
Megatrend Investing: ASX players to capitalise on the clean energy transition
Find out how you can benefit from global megatrends.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,683.40 | 50.00 | 0.58% |
| CAC 40 | 7,879.93 | 26.47 | -0.33% |
| DAX 40 | 21,552.15 | 46.45 | 0.22% |
| Dow JONES (US) | 44,623.59 | 67.55 | 0.15% |
| FTSE 100 | 8,617.15 | 46.38 | 0.54% |
| HKSE | 20,597.09 | 192.87 | -0.93% |
| NASDAQ | 19,590.68 | 63.34 | -0.32% |
| Nikkei 225 | 38,831.48 | 33.11 | 0.09% |
| NZX 50 Index | 12,844.59 | 60.45 | -0.47% |
| S&P 500 | 6,034.08 | 3.80 | -0.06% |
| S&P/ASX 200 | 8,416.90 | 42.90 | 0.51% |
| SSE Composite Index | 3,229.49 | 21.11 | -0.65% |